Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg N Brooke

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Cancer Research|December 21, 2010
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growthGreg N Brooke, Rachel L Culley, D Alwyn Dart, et al.
Nature Communications|January 31, 2026
Reliable repurposing of the antibody interactome inside the cellCaitlin M O'Shea, Rushba Shahzad, Kimia Aghasoleimani, et al.
Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.
Clinical Epigenetics|April 2, 2024
Nucleosome reorganisation in breast cancer tissuesDivya R Jacob, Wilfried M Guiblet, Hulkar Mamayusupova, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Cancer Research|December 21, 2010
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growthGreg N Brooke, Rachel L Culley, D Alwyn Dart, et al.
Nature Communications|January 31, 2026
Reliable repurposing of the antibody interactome inside the cellCaitlin M O'Shea, Rushba Shahzad, Kimia Aghasoleimani, et al.
Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.
Clinical Epigenetics|April 2, 2024
Nucleosome reorganisation in breast cancer tissuesDivya R Jacob, Wilfried M Guiblet, Hulkar Mamayusupova, et al.
Pageof 3